Display options
Cite
Kus T, Aktas G, Sevinc A, et al. Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer. Mol Clin Oncol. 2015;4(2):290-292doi: 10.3892/mco.2015.677.
Kus, T., Aktas, G., Sevinc, A., Oktay, C., Kalender, M. E., & Camci, C. (2016). Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer. Molecular and clinical oncology, 4(2), 290-292. https://doi.org/10.3892/mco.2015.677
Kus, Tulay, et al. "Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer." Molecular and clinical oncology vol. 4,2 (2016): 290-292. doi: https://doi.org/10.3892/mco.2015.677
Kus T, Aktas G, Sevinc A, Oktay C, Kalender ME, Camci C. Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer. Mol Clin Oncol. 2016 Feb;4(2):290-292. doi: 10.3892/mco.2015.677. Epub 2015 Nov 13. PMID: 26893877; PMCID: PMC4734193.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2016 Feb;4(2):290-292. doi: 10.3892/mco.2015.677. Epub 2015 Nov 13.

Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer.

Molecular and clinical oncology

Tulay Kus, Gokmen Aktas, Alper Sevinc, Cemil Oktay, Mehmet Emin Kalender, Celaletdin Camci

Affiliations

  1. Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, School of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey.
  2. Department of Radiology, School of Medicine, Akdeniz University, Antalya TR-07100, Turkey.

PMID: 26893877 PMCID: PMC4734193 DOI: 10.3892/mco.2015.677

Abstract

Hepatocellular carcinoma (HCC) and renal cell cancer (RCC) are malignancies, which are chemotherapy resistant and fatal at the advanced stages. Previously developed tyrosine kinase inhibitors are used in the treatment of advanced stage disease. In the present case study, a patient using sunitinib for stage IV RCC presented with HCC following 2 years of treatment. A patient who exhibited Child-Pugh class C cirrhosis initially, exhibited a marked improvement of hepatocellular parenchyma findings following treatment with sunitinib. Sunitinib is suggested to have preventive effects on the pathogenesis of liver fibrosis and cirrhosis

Keywords: cirrhosis; hepatocellular carcinoma; renal cell cancer; sorafenib; sunitinib

References

  1. Hepatology. 1993 Jul;18(1):47-53 - PubMed
  2. J Clin Oncol. 2013 Nov 10;31(32):4067-75 - PubMed
  3. Cancer. 2010 Jul 15;116(14):3378-88 - PubMed
  4. Biosci Trends. 2014 Dec;8(6):333-8 - PubMed
  5. Eur J Pharmacol. 2013 Apr 5;705(1-3):86-95 - PubMed
  6. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  7. Eur Urol. 2015 Nov;68(5):837-47 - PubMed
  8. Hepatol Res. 2014 May;44(5):523-31 - PubMed
  9. Curr Opin Urol. 2015 Sep;25(5):402-10 - PubMed
  10. Mol Cancer Ther. 2008 Oct;7(10 ):3129-40 - PubMed
  11. Lancet Oncol. 2009 Jan;10(1):25-34 - PubMed
  12. Eur J Cancer. 2015 Nov;51(16):2368-74 - PubMed
  13. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  14. Dig Liver Dis. 2013 Aug;45(8):692-8 - PubMed
  15. Int J Cancer. 2013 May 15;132(10):2448-58 - PubMed

Publication Types